Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
Conditions
Interventions
Olaratumab
Pembrolizumab (KEYTRUDA®)
Locations
6
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium
Herlev and Gentofte Hospital
Herlev, Denmark
Gustave Roussy
Villejuif, France
Start Date
July 3, 2017
Primary Completion Date
May 6, 2021
Completion Date
February 21, 2023
Last Updated
October 23, 2024
NCT07156565
NCT02701153
NCT07432932
NCT07222735
NCT06500065
NCT06797999
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions